Abstract
Between 1900 and 1914, a major sleeping sickness epidemic arose in many parts of Africa. Despite the competitive nature of European science in this period, the German immunologist Paul Ehrlich developed a collaborative transnational network of researchers and clinicians who worked together to carry out drug therapy trials on sleeping sickness patients in numerous African colonies. This kind of collaboration was possible when researchers shared complementary goals, and collectively this network played a significant role in shaping part of the European response to controlling an epidemic disease in Africa. Together with demonstrating how and why Ehrlich and his partners cooperated across nations and borders in their search for a drug that would cure the disease, this essay also explores what effect the drug trials had on African patients in Entebbe, British Uganda, and in Brazzaville, the capital of French Equatorial Africa.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
